Literature DB >> 29806492

Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review.

Angelina F Gomez1, Abigail L Barthel1, Stefan G Hofmann1.   

Abstract

INTRODUCTION: Generalized anxiety disorder (GAD) is a common form of anxiety disorder. Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and benzodiazepines (BZs) are the most commonly prescribed medications for GAD, but little is known about the relative efficacy of these pharmacological treatments. Areas covered: This study provides a meta-analytic review of the efficacy of these medications in the treatment of adults with GAD. A comprehensive literature search yielded 54 articles reporting 56 unique studies with 12,655 participants treated with either pill placebo (6,191 participants), SSRIs (16 trials, 2,712 participants), SNRIs (17 trials, 2,603 participants), or BZs (23 trials, 1,149 participants). The overall combined effect size was modest to moderate (Hedges' g = 0.37, p < 0.0001). Effect sizes decreased significantly over time. SSRIs (Hedges' g = 0.33) and SNRIs (Hedges' g = 0.36) demonstrated significantly lower effect sizes than BZs (Hedges' g = 0.50). These findings were not due to differences in treatment length or publication year. Expert opinion: The results of this study suggest that the most common forms of pharmacotherapy for adult GAD are moderately effective, with BZs being the most effective drug.

Entities:  

Keywords:  GAD; Generalized anxiety disorder; SNRI; SSRI; benzodiazepines; medication; meta-analysis; pharmacotherapy

Mesh:

Substances:

Year:  2018        PMID: 29806492      PMCID: PMC6097846          DOI: 10.1080/14656566.2018.1472767

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  90 in total

Review 1.  Predictors of Pharmacotherapy Response in Generalized Anxiety Disorder: A Systematic Review.

Authors:  Rafael Ferreira-Garcia; Marina Mochcovitch; Mariana Costa do Cabo; Antonio Egídio Nardi; Rafael Christophe Freire
Journal:  Harv Rev Psychiatry       Date:  2017 Mar/Apr       Impact factor: 3.732

2.  A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder.

Authors:  Kristin Mitte; Peter Noack; Regina Steil; Martin Hautzinger
Journal:  J Clin Psychopharmacol       Date:  2005-04       Impact factor: 3.153

3.  Pregabalin in generalized anxiety disorder: a placebo-controlled trial.

Authors:  Atul C Pande; Jerri G Crockatt; Douglas E Feltner; Carol A Janney; Ward T Smith; Richard Weisler; Peter D Londborg; Robert J Bielski; Dan L Zimbroff; Jonathan R T Davidson; Maria Liu-Dumaw
Journal:  Am J Psychiatry       Date:  2003-03       Impact factor: 18.112

4.  Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.

Authors:  Dan J Stein; Antti Ahokas; Miguel S Márquez; Cyril Höschl; Kang Seob Oh; Marek Jarema; Alla S Avedisova; Cristina Albarran; Valérie Olivier
Journal:  J Clin Psychiatry       Date:  2014-04       Impact factor: 4.384

5.  An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.

Authors:  Rosario B Hidalgo; Larry A Tupler; Jonathan R T Davidson
Journal:  J Psychopharmacol       Date:  2007-11       Impact factor: 4.153

6.  Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder.

Authors:  R Enkelmann
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

7.  Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.

Authors:  H Nicolini; D Bakish; H Duenas; M Spann; J Erickson; C Hallberg; S Ball; D Sagman; J M Russell
Journal:  Psychol Med       Date:  2008-05-19       Impact factor: 7.723

8.  A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder.

Authors:  David Hackett; Vincent Haudiquet; Eliseo Salinas
Journal:  Eur Psychiatry       Date:  2003-06       Impact factor: 5.361

9.  A fixed-dose study of adinazolam-SR tablets in generalized anxiety disorder.

Authors:  C S Wilcox; P J Ryan; J L Morrissey; J B Cohn; D F DeFrancisco; R D Linden; J F Heiser
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1994-10       Impact factor: 5.067

10.  Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorder.

Authors:  Luís Ferreira; Maria-Luísa Figueira; Alberto Bessa-Peixoto; António Marieiro; Rodolfo Albuquerque; Cristina Paz; Ana Cerqueira; Pedro Damião; Ana Dolgner; Jasper Dingemanse
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

View more
  17 in total

Review 1.  Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders.

Authors:  Thomas Prévot; Etienne Sibille
Journal:  Mol Psychiatry       Date:  2020-04-28       Impact factor: 15.992

Review 2.  Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review.

Authors:  Jeffrey R Strawn; Laura Geracioti; Neil Rajdev; Kelly Clemenza; Amir Levine
Journal:  Expert Opin Pharmacother       Date:  2018-07       Impact factor: 3.889

3.  The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses.

Authors:  Falk Leichsenring; Christiane Steinert; Sven Rabung; John P A Ioannidis
Journal:  World Psychiatry       Date:  2022-02       Impact factor: 49.548

Review 4.  The prefrontal cortex, pathological anxiety, and anxiety disorders.

Authors:  Margaux M Kenwood; Ned H Kalin; Helen Barbas
Journal:  Neuropsychopharmacology       Date:  2021-08-16       Impact factor: 8.294

5.  Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles.

Authors:  Thomas D Prevot; Guanguan Li; Aleksandra Vidojevic; Keith A Misquitta; Corey Fee; Anja Santrac; Daniel E Knutson; Michael Rajesh Stephen; Revathi Kodali; Nicolas M Zahn; Leggy A Arnold; Petra Scholze; Janet L Fisher; Bojan D Marković; Mounira Banasr; James M Cook; Miroslav Savic; Etienne Sibille
Journal:  Mol Neuropsychiatry       Date:  2019-01-23

Review 6.  Anxiety disorders.

Authors:  Brenda Wjh Penninx; Daniel S Pine; Emily A Holmes; Andreas Reif
Journal:  Lancet       Date:  2021-02-11       Impact factor: 202.731

7.  Efficacy of Yoga vs Cognitive Behavioral Therapy vs Stress Education for the Treatment of Generalized Anxiety Disorder: A Randomized Clinical Trial.

Authors:  Naomi M Simon; Stefan G Hofmann; David Rosenfield; Susanne S Hoeppner; Elizabeth A Hoge; Eric Bui; Sat Bir S Khalsa
Journal:  JAMA Psychiatry       Date:  2021-01-01       Impact factor: 21.596

8.  "It could potentially be dangerous... but nothing else has seemed to help me.": Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment.

Authors:  Tae Woo Park; Jennifer Sikov; Vanessa dellaBitta; Richard Saitz; Alexander Y Walley; Mari-Lynn Drainoni
Journal:  J Subst Abuse Treat       Date:  2021-04-30

9.  Behavioral Deficits Induced by Somatostatin-Positive GABA Neuron Silencing Are Rescued by Alpha 5 GABA-A Receptor Potentiation.

Authors:  Corey Fee; Thomas D Prevot; Keith Misquitta; Daniel E Knutson; Guanguan Li; Prithu Mondal; James M Cook; Mounira Banasr; Etienne Sibille
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-14       Impact factor: 5.176

Review 10.  Fatigue as the Chief Complaint–Epidemiology, Causes, Diagnosis, and Treatment.

Authors:  Peter Maisel; Erika Baum; Norbert Donner-Banzhoff
Journal:  Dtsch Arztebl Int       Date:  2021-08-23       Impact factor: 8.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.